CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancerErin M. Bange, John P. Reilly, Sigrid Gouma et al.|Nature Medicine|2021Cited by 519
Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration*Nuala J. Meyer, Steven M. Opal, John P. Reilly et al.|Critical Care Medicine|2017Cited by 98